Please login to the form below

Not currently logged in
Email:
Password:

Redx Pharma appoints new chief medical officer

Dr Andrew Saunders joins the UK biotech from Lytix Biopharma

Dr Andrew SaundersDrug discovery and development group Redx Pharma has appointed Dr Andrew Saunders as its chief medical officer (CMO), a role that will see him work with the R&D team fronting the clinical development of the company’s lead candidate.

Dr Saunders has worked in the oncology field for over 25 years and has experience in all aspects of the clinical development of oncology drugs.

He joins the UK biotech from Lytix Biopharma, a Norweigan immuno-oncology biotech, where he also served as CMO.

During his career, Dr Saunders has held several roles for both pharma and biotech companies, including Genzyme - now part of Sanofi, Roche, and Eli Lilly.

Ian Ross, chairman of Redx Pharma, said: “Dr Saunders brings a wealth of relevant experience and expertise in the clinical development of oncology drugs, which will be invaluable as the company transforms into a clinical stage company with the anticipated commencement of the first phase I study on lead compound RXC004.”

25th January 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Infographics